LDLR and metabolic dysfunction-associated steatotic liver disease: Research findings indicate that inflammatory responses trigger heightened activity of mammalian target of rapamycin complex 1 (mTORC1), disrupting transcription and post-transcriptional mechanisms, impairing the expression of low-density lipoprotein receptor (LDLR), and exacerbating the progression of non-alcoholic fatty liver disease [22].